## VPA10996/285/001

## Vecoxan 2.5 mg/ml Oral Suspension for lambs and calves

Variation	Summary	Date
Vet - B48	VNRA - Vet - B48 Vet - B48 - Addition or replacement	
	of a measuring or administration device which is not an	22/12/25
	integrated part of the primary packaging	
Vet - B35 b)	VNRA - Vet - B35 b) - b) Addition of a new specification	
	parameter to the specification with its corresponding test	
	method - B35 b) Changes to the quality part of the dossier:	
	Change in the specification parameters or limits of the	07/11/24
	immediate packaging of the finished product: — addition	
	of a new specification parameter to the specification with	
	its corresponding test method	
Vet - B24 a)	VNRA - Vet – B24 a) - B24 Replacement or addition of a	
	manufacturer responsible for a) - B24 Replacement or	
	addition of a manufacturer responsible for a)- batch	08/04/24
	release including batch control or testing of a sterile or	
	non-sterile finished product	
	VNRA - Vet - B21 - Replacement or addition of a	08/04/24
	secondary packaging site of a finished product - B21	
Vet - B21	Changes to the quality part of the dossier: Replacement or	
	addition of a secondary packaging site of a finished	
	product	
	VNRA - Vet - B47 b) - b) Change to comply with an	08/04/24
	update of the relevant monograph of the Ph. Eur. or	
	national pharmacopoeia of a Member State - B47 b)	
Vet - B47 b)	Changes to the quality part of the dossier: Change to	
	comply with Ph. Eur. or with a national pharmacopoeia of	
	a Member State: — change to comply with an update of	
	the relevant monograph of the Ph. Eur. or national	
	pharmacopoeia of a Member State	
N	VNRA - Vet - B20 - Replacement or addition of a primary	
	packaging site of a non-sterile finished product - B20	08/04/24
Vet - B20	Changes to the quality part of the dossier: Replacement or	
	addition of a primary packaging site of a non-sterile	
	finished product  VRA-S - Vet - F.I.b.1 z) - z) Other changes under this	
	code level e.g. variations outlined in section 6 and 7 of	08/04/24
	EMA/CMDv/7381/2021 - F.I.b.1 z) Quality Changes -	
	Active Substance - Control of active substance - Change in	
Vet - F.I.b.1 z)	the specification parameters and/or limits of an active	
	substance, starting material/intermediate/reagent used in	
	the manufacturing process of the active substance - Other	
	changes under this code level, e.g. variations outlined in	
	section 6 and 7 of EMA/CMDv/7381/2021	
Vet - F.II.e.2 z)	VRA-S - Vet - F.II.e.2 z) - z) Other changes under this	00/04/5
	code level e.g. variations outlined in section 6 and 7 of	08/04/24

<b>_</b>	Tr. ( + ( G) ( F) ( F G) ( + ( G) ( F)	1
	EMA/CMDv/7381/2021 - F.II.e.2 z) Quality Changes - Container closure system - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	
Vet - F.II.e.1 a) 1.	VRA-S - Vet - F.II.e.1 a) 1 a) Qualitative and quantitative composition 1. Semi-solid and non-sterile liquid pharmaceutical forms - F.II.e.1 a) 1. Quality Changes - Container closure system - Change in immediate packaging of the finished product - Semi-solid and non-sterile liquid pharmaceutical forms	08/04/24
Vet - F.II.d.1 z)	VRA-S - Vet - F.II.d.1 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.d.1 z) Quality Changes - Finished Product -Control of finished product - Change in the specification parameters and/or limits of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	08/04/24
Vet - F.II.d.2 b)	VRA-S - Vet - F.II.d.2 b) - b) Other changes to a test procedure (including replacement or addition) - F.II.d.2 b) Quality Changes - Finished Product -Control of finished product - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	08/04/24
Vet - F.II.c.1 z)	VRA-S - Vet - F.II.c.1 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.c.1 z) Quality Changes - Finished Product -Control of excipients-Change in the specification parameters and/or limits of an excipient - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	08/04/24
Vet - F.II.b.1 c)	VRA-S - Vet - F.II.b.1 c) - c) Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products - F.II.b.1 c) Quality Changes - Finished Product - Manufacture - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products	08/04/24
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with	04/04/24

	Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	
Vet - B26 a)	VNRA - Vet - B26 a) - a) Up to 10-fold increase compared to the originally approved batch size of an immediate release oral pharmaceutical forms or of a non-sterile liquid based pharmaceutical form - B26 a) Changes to the quality part of the dossier: Change in the batch size (including batch size ranges) of the finished product: — up to 10-fold increase compared to the originally approved batch size of an immediate release oral pharmaceutical forms or of a non-sterile liquid based pharmaceutical form	16/01/24
Vet - B44(Do not use)	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	16/01/24
C.II.7.b	IB - C.II.7.b - b) Which has been assessed by the relevant national competent authority/EMA for another product of the same MAH(*) - C.II.7.b - SAFETY, EFFICACY, PHARMACOVIGILANCE CHANGES - VETERINARY MEDICINAL PRODUCT ?SPECIFIC CHANGES - Introduction of a new Pharmacovigilance system - Which has been assessed by the relevant national competent authority/EMA for another product of the same MAH(*)	02/02/22